ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL being validated as a target of CML, BCR-ABL specific tyrosine kinase inhibitors (TKIs), Imatinib (IM), Nilotinib, and Dasatinib, have been widely used in clinic.